Opinion

Video

Beyond Step Edits: Treatment Strategy After Bevacizumab in nAMD

Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.

This is a video synopsis of a discussion involving Ehsan Rahimy, MD, a retina specialist at the Palo Alto Medical Foundation and adjunct faculty at Stanford University School of Medicine. Dr. Rahimy explores various scenarios for managing patients with wet age-related macular degeneration (AMD) or diabetic macular edema (DME).

In one scenario, if a patient with 20/30 vision and a central subfield thickness (CST) of 350 microns shows stability in subjective and objective vision without recurrent fluid, Dr. Rahimy advocates for a treat-and-extend approach. He gradually extends treatment intervals from four to twelve weeks, noting some patients even extend up to 16 to 18 weeks post-COVID era, with various agents like aflibercept or ranibizumab.

Another scenario entails encountering resistance to extension after initial success. Dr. Rahimy discusses patient preferences for shorter treatment intervals despite favorable outcomes, while others are motivated to extend intervals. In such cases, he considers switching to branded agents like aflibercept or faricimab to achieve increased durability and extend intervals up to three or four months.

Lastly, Dr. Rahimy addresses scenarios where patients exhibit persistence of fluid despite treatment, indicating a lack of response to bevacizumab. Despite potential vision improvement, achieving complete dryness remains the goal before extending intervals. Early therapy switching may be necessary to attain optimal anatomical outcomes.

Dr. Rahimy's insights underscore the nuanced approach required in managing patients with AMD or DME, considering factors such as treatment response, patient preferences, and the pursuit of optimal anatomical outcomes.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.